AIVF develops AI-supported software for fertility clinics and laboratories.
Introduce me to AIVF
Image source: company website sharing image
Founders & company facts
Sources reviewed:Reported cumulative funding
$25,000,000 · Source
This index includes companies with publicly reported total funding up to US$150 million. This is a reported total, not valuation, the latest round size or confirmation of an open round. Funding reviewed: .
Documented founding team
- Daniella GilboaSource: Daniella Gilboa
- Prof. Daniel SeidmanSource: Prof. Daniel Seidman
- Founded
- 2018Source
- Reported Israeli location
- Tel Aviv-YafoSource
- Team range in directory
- 11-50Source
- Reported business model
- B2BSource
Selected disclosed financing
Selected transactions, with dates, funding types and reported participants.
- Jun 2022$25MSeries A
Company overview
Product & customers
AIVF develops AI-supported software for fertility clinics and laboratories. Its EMA platform combines embryo assessment tools with a digital workspace for care-team information and treatment workflows.
Commercial potential · editorial analysis
The commercial opportunity is improving consistency and coordination in fertility laboratories where specialist time and careful documentation shape clinic capacity. Investors should distinguish paid use and renewals from pilots, and examine how sales and delivery costs change as deployments expand.
What to validate
Diligence should focus on prospective outcome evidence, selection bias, laboratory compatibility and clear separation between decision support and clinical responsibility. Evidence should come from representative customer deployments, with costs, limitations and failure cases reported alongside successful results.
Product source reviewed on . Company source